Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daunorubicin/Cytarabine Liposomes + Venetoclax vs Azacitidine + Venetoclax in Newly Diagnosed AML
NCT06770257Phase 2Withdrawn
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
01
Overview
Phase 2, randomised, open-label trial of daunorubicin + cytarabine liposome in acute myeloid leukemia (AML) (3 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Complete Remission Rate at 8 months. Planned start Dec 2025; status: withdrawn.
02
Drugs
daunorubicin + cytarabine liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06770257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06770257.